00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
23:06 , Dec 20, 2018 |  BC Extra  |  Company News

Barrett joins pharma exodus for biotech

Novartis AG (NYSE:NVS; SIX:NOVN) named its third CEO of oncology in 11 months as Elizabeth Barrett joins the exodus of pharma leaders heading to biotech. Barrett said she will become CEO of an undisclosed U.S.-based...
18:08 , Oct 19, 2018 |  BC Week In Review  |  Company News

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire cancer company Endocyte Inc. (NASDAQ:ECYT) for about $2.1 billion in cash. The deal gives Novartis 177Lu-PSMA-617, a radioligand therapy in the Phase III VISION trial to treat prostate-specific membrane...
17:47 , Oct 18, 2018 |  BC Extra  |  Company News

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire cancer company Endocyte Inc. (NASDAQ:ECYT) for about $2.1 billion in cash. The deal gives Novartis 177Lu-PSMA-617, a radioligand therapy in the Phase III VISION trial to treat prostate-specific membrane...
18:39 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Altheia lands $11M series A

Altheia Science s.r.l. (Milan, Italy) closed an $11 million series A round. The round could be expanded by another $6.7 million with the participation of institutional investors, the company said. Paolo Rizzardi, Altheia's chairman and...
22:33 , Sep 24, 2018 |  BC Extra  |  Financial News

Altheia lands $11M series A

Altheia Science S.r.l. (Milan, Italy) closed an $11 million series A round. The round could be expanded by another $6.7 million with the participation of institutional investors, the company said. Paolo Rizzardi, Altheia's chairman and...
19:08 , Jan 26, 2018 |  BC Extra  |  Company News

FDA approves Novartis' Lutathera for GEP-NETs

FDA approved Lutathera (177-Lu-Dotatate) from Novartis AG (NYSE:NVS; SIX:NOVN) to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults, including foregut, midgut, and hindgut neuroendocrine tumors. Novartis gained the drug when it acquired Advanced Accelerator...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
23:56 , Nov 3, 2017 |  BioCentury  |  Strategy

Broadening Novartis’ NET

Novartis AG’s proposed acquisition of Advanced Accelerator Applications S.A. would broaden the pharma’s neuroendocrine tumor franchise by providing it with a second-line agent -- Lutathera -- that addresses patients with progressive, symptomatic disease. On Oct....
04:51 , Nov 3, 2017 |  BC Week In Review  |  Company News

Novartis offers $3.9B to acquire Advanced Accelerator

Novartis AG (NYSE:NVS; SIX:NOVN) offered to acquire Advanced Accelerator Applications S.A. (NASDAQ:AAAP) for $82 per ADS in a deal the companies say values Advanced Accelerator at $3.9 billion. The price is a 12% premium on...